An article published online on February 20, 2009 in the journal Archives of Biochemistry and Biophysics reported the benefits of the antioxidant compound alpha-lipoic acid in lowering triglycerides. High triglyceride levels often occur in obesity, and are a predictor of atherosclerosis, nonalcoholic fatty liver disease, and even premature mortality. Proper diet, exercise, and weight loss can help reduce triglycerides, but are not effective for everyone.
For the current research, Regis Moreau and colleagues at Oregon State University’s Linus Pauling Institute used rats bred to become obese and diabetic. At five weeks of age, the animals were given 200 milligrams per kilogram body weight R-alpha-lipoic acid per day. Control rats were matched for food intake with the animals that received lipoic acid during the five week treatment period.
Not unexpectedly, triglyceride levels following meals were higher by the end of the study compared to pretreatment levels. However, while triglyceride levels doubled among those that received alpha-lipoic acid, they increased by over 400 percent in the control group.
Alpha-lipoic acid’s mechanisms include inhibition of specific gene expression in the liver, lowering liver triglyceride secretion, and stimulating the clearance of triglyceride-rich lipoproteins. When the animals’ livers were examined at the study’s conclusion, those from rats treated with lipoic acid showed elevated glycogen levels, which suggests that more consumed carbohydrates were being stored as glycogen rather than becoming triglycerides.
According to the authors, the study is the first to identify the lipoic acid’s molecular targets in lowering triglycerides, and to show its effect on liver enzymes that control triglyceride production. Although the benefit of lipoic acid on triglyceride levels was comparable to that of currently used drugs, the mode of action was determined to differ from fibrates. Importantly, supplementation with alpha-lipoic acid has not been associated with the side effects and safety concerns of pharmaceuticals used to treat hypertriglyceridemia.
“Lipoic acid is known to influence glucose uptake, and bring down blood glucose by increasing its transport into skeletal muscle,” stated Dr Moreau, who is an assistant professor at the Linus Pauling Institute. “Less has been done to study its potential value in reducing triglycerides.”
“The extent of triglyceride reduction was really dramatic, we didn’t expect it to be this profound,” he remarked. “The potential is good that this could become another way to lower blood triglycerides and help reduce the risk of atherosclerosis. It’s pretty exciting.”
“We believe that a novel means of controlling triglyceridemia in this animal model has been revealed,” the authors write. “Given its strong safety record, lipoic acid may have therapeutic applications for the treatment or prevention of hypertriglyceridemia and diabetic dyslipidemia in humans.”